Merck to buy drug developer Pandion Therapeutics for $1.85B
February 25, 2021 at 09:49 AM EST
Pandion’s lead drug candidate, PT101, last month met its main goals of safety and tolerability in an early-stage trial in patients with autoimmune diseases.
